Category Archives: Novo Nordisk

AskNadia: Skin Reaction to Levemir Insulin

Dear Nadia,

I injected Levemir insulin and now I have a ball. Is that normal? It itches as well.

Michelle

Dear Michelle,

Skin reactions to insulin injection are not new. Since the advent of insulin in 1922, people taking injections …

Weekly Dulaglutide Performs Well in Comparison to Daily Liraglutide

A comparison of the effects on A1c between users of once-weekly dulaglutide (made by Eli Lilly and Company) and once-daily liraglutide (sold as Victoza from Novo Nordisk) shows that both drugs have very similar effects.

Researchers at Ohio State University …

Novo Nordisk Introduces New Insulin Device to U.S. Market

Novo Nordisk has introduced the Levemir® FlexTouch® prefilled insulin delivery device to the U.S. market. The device, filled with insulin detemir [rDNA origin], the first of its kind that does not use a pushbutton extension. In a conventional insulin delivery …

Fewer Hypoglycemic Episodes With One Insulin in Head-to-Head Comparison

A recently completed study that compared two types of insulin for treating inadequately controlled type 2 patients showed that insulin degludec/insulin aspart produced fewer instances of hypoglycemia than biphasic insulin aspart 30.

However, both types of insulin were equally effective …

NBA Hall of Famer Dominique Wilkins: Has A Slam Dunk Formula for Diabetes

NBA Hall of Famer Dominique Wilkins, affectionately known as “The Human Highlight Film” has a few coaching tips for people with diabetes.

Several years after retiring from the Atlanta Hawks, Dominique was diagnosed with type 2 diabetes. Once he stopped …

FDA Backtracks Over GLP-1s’ Effects on Pancreas

The U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a link between GLP-1 drugs used to treat type 2 diabetes and pancreatic maladies, including acute pancreatitis and pancreatic cancer.

GLP-1 …

Weekly Type 2 Drug to Be Delivered Via Needle Patch

A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system.

The drug, now under development by Novo Nordisk, is semaglutide, …